Abstract:
The present disclosure proposes a fully integrated accurate LED output current controlling circuit and method, which can be seamlessly combined with true PWM dimming. The current controlling circuit has an auto zero function in the light-emitting diode driver to eliminate offsets caused by the system, process variations, parasitic effects, dimming and so on in an LED driver application, and thus is capable of controlling the LED current with high accuracy. Moreover, the driver of the present disclosure does not require the use of external components such as an external resistor to regulate current accuracy.
Abstract:
The present disclosure proposes a fully integrated accurate LED output current controlling circuit and method, which can be seamlessly combined with true PWM dimming. The current controlling circuit has an auto zero function in the light-emitting diode driver to eliminate offsets caused by the system, process variations, parasitic effects, dimming and so on in an LED driver application, and thus is capable of controlling the LED current with high accuracy. Moreover, the driver of the present disclosure does not require the use of external components such as an external resistor to regulate current accuracy.
Abstract:
An ESD protection circuit for a switching power converter which includes a high-side switching element connected between a supply voltage and the switching node, and a low-side switching element connected between the switching node and a common node. A current conduction path couples an ESD event that occurs on the switching node to an ESD sense node, and an ESD sensing circuit coupled to the sense node generates a trigger signal when an ESD event is sensed. A first logic gate keeps the high-side switching element off when the trigger signal indicates the sensing of an ESD event, and a second logic gate causes the low-side switching element to turn on when an ESD event is sensed such that the low-side switching element provides a conductive discharge path between the switching node and common node.
Abstract:
The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, R1b, R2a, R2b, R2c, A1, A2, and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
Abstract:
A carotenoid oil suspension and preparation method thereof are provided. The method includes the following steps: a) mixing carotenoid with organic solvent, heating the mixture to dissolve the carotenoid sufficiently to obtain carotenoid solution; b) introducing the carotenoid solution obtained in step a) into a vegetable oil solution stirred in high speed by spraying, meanwhile recovering the organic solvent generated during spraying under vacuum condition, then, simultaneously completing recycling and spraying, thereafter, obtaining carotenoid oil suspension; wherein, the carotenoid oil suspension comprises a carotenoid crystal with an average particle size of less than 5 μm. The method is applicable in industrial scale with continuous operation and increased efficiency without additional carotenoid crystal grinding processes, and decreases the degradation of carotenoid during the preparation process of carotenoid oil suspension.
Abstract:
The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
Abstract:
The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
Abstract:
The invention relates to compounds of Formulae I(a) to XI and pharmaceutically acceptable salts and solvates thereof (Proline Analog Compounds), that are useful, e.g., as ligands for cannabinoid receptors, as compositions comprising a Proline Analog Compound and a pharmaceutically acceptable carrier, in methods of making such Proline Analog Compounds, and in methods for treating or preventing a Condition, such as pain, nausea, vomiting and an eating disorder, comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.
Abstract:
This invention relates aryl substituted pyridines of Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1-R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
Abstract:
The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.